Clinical Trial Update: Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL [Phase 2]

View source ↗

Summary

Phase II trial evaluating the safety and efficacy of CB-103 in combination with Venetoclax for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• CB-103
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoblastic, Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2025-11-26